SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:5ca33b1e-777b-4f65-915b-ad3d440673cc"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:5ca33b1e-777b-4f65-915b-ad3d440673cc" > Usefulness of Verna...

Usefulness of Vernakalant Hydrochloride Injection for Rapid Conversion of Atrial Fibrillation

Pratt, Craig M. (författare)
Roy, Denis (författare)
Torp-Pedersen, Christian (författare)
visa fler...
Wyse, D. George (författare)
Toft, Egon (författare)
Juul-Möller, Steen (författare)
Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine
Retyk, Enrique (författare)
Drenning, David Humphrey (författare)
visa färre...
 (creator_code:org_t)
Elsevier BV, 2010
2010
Engelska.
Ingår i: American Journal of Cardiology. - : Elsevier BV. - 1879-1913 .- 0002-9149. ; 106:9, s. 1277-1283
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR) Patients with either AF or atrial flutter were randomized in a 11 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to <= 7 days (short duration) and 8 to <= 45 days (long duration) The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated A total of 265 patients were randomized and received treatment The primary end point was conversion of AF to SR for >= 1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51 2%) demonstrated conversion to SR compared to 3 (3 6%) of the 84 in the placebo group (p <0 0001) The median interval to conversion of short-duration AF to SR in the responders given vernakalant was 8 minutes Of the entire AF population (short- and long-duration AF), 47 (39 8%) of the 118 vernakalant patients experienced conversion of AF to SR compared to 4 (3 3%) of the 121 placebo patients (p <0 0001) Transient dysgeusia and sneezing were the most common adverse events in the vernakalant patients One vernakalant patient who had severe aortic stenosis experienced hypotension and ventricular fibrillation and died In conclusion, vernakalant demonstrated a rapid and high rate of conversion for short-duration AF and was well tolerated (C) 2010 Elsevier Inc All rights reserved (Am J Cardiol 2010,106 1277-1283)

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy